Orphan drugs to treat myasthenia gravis

Bibliography

• Grob D, Brunner N, Namba T, et al. Lifetime course of myasthenia gravis. Muscle Nerve 2008;37:141-9
   PubMed Web of Science ®Google Scholar
• Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009;8:475-90
   PubMed Web of Science ®Google Scholar
• Aarli JA. Myasthenia gravis in the elderly: is it different? Ann NY Acad Sci 2008;1132:238-43
   PubMed Web of Science ®Google Scholar
• Phillips LH II. The epidemiology of myasthenia gravis. Ann NY Acad Sci 2003;998:407-12
   PubMed Web of Science ®Google Scholar
• Aragones JM, Bolibar I, Bonfill X, et al. Myasthenia gravis: a higher than expected incidence in the elderly. Neurology 2003;60:1024-6
   PubMed Web of Science ®Google Scholar
• Vincent A, Clover L, Buckley C, et al. Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry 2003;74:1105-8
   PubMed Web of Science ®Google Scholar
• Wolfe GI, Oh SJ. Clinical phenotype of muscle-specific tyrosine kinase-antibody-positive myasthenia gravis. Ann NY Acad Sci 2008;1132:71-5
   PubMedGoogle Scholar
• Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 2011;69:418-22
   PubMed Web of Science ®Google Scholar
• Pevzner A, Schoser B, Peters K, et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 2012;259:427-35
   PubMed Web of Science ®Google Scholar
• Zhang B, Tzartos JS, Belimezi M, et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 2012;69:445-51
   PubMed Web of Science ®Google Scholar
• Leite MI, Jacob S, Viegas S, et al. IgG1 antibodies to acetylcholine receptors in ‘seronegative' myasthenia gravis. Brain 2008;131:1940-52
   PubMed Web of Science ®Google Scholar
• Deymeer F, Gungor-Tuncer O, Yilmaz V, et al. Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis. Neurology 2007;68:609-11
   PubMed Web of Science ®Google Scholar
• Baggi F, Andreetta F, Maggi L, et al. Complete stable remission and autoantibody specificity in myasthenia gravis. Neurology 2013;80:188-95
   PubMed Web of Science ®Google Scholar
• Selcen D, Fukuda T, Shen XM, et al. Are MuSK antibodies the primary cause of myasthenic symptoms? Neurology 2004;62:1945-50
   PubMed Web of Science ®Google Scholar
• Shiraishi H, Motomura M, Yoshimura T, et al. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 2005;57:289-93
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Ito M, Hirayama M, et al. Anti-MuSK autoantibodies block binding of collagen Q to MuSK. Neurology 2011;77:1819-26
   PubMed Web of Science ®Google Scholar
• Evoli A, Minisci C, Di Schino C, et al. Thymoma in patients with MG: characteristics and long-term outcome. Neurology 2002;59:1844-50
   PubMed Web of Science ®Google Scholar
• Cavalcante P, Barberis M, Cannone M, et al. Detection of poliovirus-infected macrophages in thymus of patients with myasthenia gravis. Neurology 2010;74:1118-26
   Google Scholar
• Cavalcante P, Serafini B, Rosicarelli B, et al. Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus. Ann Neurol 2010;67:726-38
   PubMed Web of Science ®Google Scholar
• Bernasconi P, Barberis M, Baggi F, et al. Increased toll-like receptor 4 expression in thymus of myasthenic patients with thymitis and thymic involution. Am J Pathol 2005;167:129-39
   PubMedGoogle Scholar
• Jaretzki A III, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55:16-23
   PubMed Web of Science ®Google Scholar
• Skeie GO, Apostolski S, Evoli A, et al. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010;137:893-902
   Google Scholar
• Thomas CE, Mayer SA, Gungor Y, et al. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 1997;48:1253-60
   PubMed Web of Science ®Google Scholar
• Engel AG, Lambert EH, Santa T. Study of long-term anticholinesterase therapy. Effects on neuromuscular transmission and on motor end-plate fine structure. Neurology 1973;23:1273-81
   PubMedGoogle Scholar
• Sieb JP, Kohler W. Benefits from sustained-release pyridostigmine bromide in myasthenia gravis: results of a prospective multicenter open-label trial. Clin Neurol Neurosurg 2010;112:781-4
   PubMed Web of Science ®Google Scholar
• Punga AR, Flink R, Askmark H, et al. Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody. Muscle Nerve 2006;34:111-15
   PubMed Web of Science ®Google Scholar
• Evoli A, Alboini PE, Bisonni A, et al. Management challenges in muscle-specific tyrosine kinase myasthenia gravis. Ann NY Acad Sci 2012;1274:86-91
   PubMed Web of Science ®Google Scholar
• Ferrero S, Pretta S, Nicoletti A, et al. Myasthenia gravis: management issues during pregnancy. Eur J Obstet Gynecol Reprod Biol 2005;121:129-38
   PubMed Web of Science ®Google Scholar
• Hoff JM, Daltveit AK, Gilhus NE. Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care. Eur J Neurol 2007;14:38-43
   PubMed Web of Science ®Google Scholar
• Fauci AS. Mechanisms of corticosteroid action on lymphocyte subpopulations. II. Differential effects of in vivo hydrocortisone, prednisone and dexamethasone on in vitro expression of lymphocyte function. Clin Exp Immunol 1976;24:54-62
   PubMed Web of Science ®Google Scholar
• Brunner NG, Berger CL, Namba T, Grob D. Corticotropin and corticosteroids in generalized myasthenia gravis: comparative studies and role in management. Ann NY Acad Sci 1976;274:577-95
   PubMed Web of Science ®Google Scholar
• Dobkin BH. Dexamethasone dosage suggested every 3-4 days in myasthenia gravis. Neurology 1977;27:202
   Google Scholar
• Lindberg C, Andersen O, Lefvert AK. Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study. Acta Neurol Scand 1998;97:370-3
   PubMed Web of Science ®Google Scholar
• Nagane Y, Suzuki S, Suzuki N, Utsugisawa K. Early aggressive treatment strategy against myasthenia gravis. Eur Neurol 2011;65:16-22
   Google Scholar
• Bolooki H, Schwartzman RJ. High-dose steroids for perioperative management of patients with myasthenia gravis undergoing thymectomy. A preliminary report. J Thorac Cardiovasc Surg 1978;75:754-7
   Google Scholar
• Komiyama A, Arai H, Kijima M, Hirayama K. Extraocular muscle responses to high dose intravenous methylprednisolone in myasthenia gravis. J Neurol Neurosurg Psychiatry 2000;68:214-17
   PubMed Web of Science ®Google Scholar
• Sghirlanzoni A, Peluchetti D, Mantegazza R, et al. Myasthenia gravis: prolonged treatment with steroids. Neurology 1984;34:170-4
   PubMed Web of Science ®Google Scholar
• Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984;15:291-8
   PubMed Web of Science ®Google Scholar
• Schneider-Gold C, Gajdos P, Toyka KV, et al. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev 2005(2):CD002828
   Google Scholar
• Hart IK, Sathasivam S, Sharshar T. Immunosuppressive agents for myasthenia gravis. Cochrane Database Syst Rev 2007(4):CD005224
   Google Scholar
• Mantegazza R, Antozzi C, Peluchetti D, et al. Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol 1988;235:449-53
   PubMed Web of Science ®Google Scholar
• Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538-49
   PubMed Web of Science ®Google Scholar
• Colleoni L, Kapetis D, Maggi L, et al. A new thiopurine S-methyltransferase haplotype associated with intolerance to azathioprine. J Clin Pharmacol 2012; Epub ahead of print
   Google Scholar
• Tindall RS, Rollins JA, Phillips JT, et al. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987;316:719-24
   PubMed Web of Science ®Google Scholar
• Perez MC, Buot WL, Mercado-Danguilan C, et al. Stable remissions in myasthenia gravis. Neurology 1981;31:32-7
   PubMedGoogle Scholar
• De Feo LG, Schottlender J, Martelli NA, et al. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve 2002;26:31-6
   PubMed Web of Science ®Google Scholar
• Nagane Y, Utsugisawa K, Obara D, et al. Efficacy of low-dose FK506 in the treatment of Myasthenia gravis: a randomized pilot study. Eur Neurol 2005;53:146-50
   PubMed Web of Science ®Google Scholar
• Yoshikawa H, Kiuchi T, Saida T, Takamori M. Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry 2011;82:970-7
   PubMed Web of Science ®Google Scholar
• Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008;71:394-9
   PubMed Web of Science ®Google Scholar
• Sanders DB, Hart IK, Mantegazza R, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008;71:400-6
   PubMed Web of Science ®Google Scholar
• Hehir MK, Burns TM, Alpers J, et al. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. Muscle Nerve 2010;41:593-8
   PubMed Web of Science ®Google Scholar
• Araga S, Xu L, Nakashima K, et al. A peptide vaccine that prevents experimental autoimmune myasthenia gravis by specifically blocking T cell help. FASEB J 2000;14:185-96
   PubMed Web of Science ®Google Scholar
• Galin FS, Chrisman CL, Cook JR Jr, et al. Possible therapeutic vaccines for canine myasthenia gravis: implications for the human disease and associated fatigue. Brain Behav Immun 2007;21:323-31
   PubMed Web of Science ®Google Scholar
• Brenner T, Hamra-Amitay Y, Evron T, et al. The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis. FASEB J 2003;17:214-22
   PubMed Web of Science ®Google Scholar
• Argov Z, McKee D, Agus S, et al. Treatment of human myasthenia gravis with oral antisense suppression of acetylcholinesterase. Neurology 2007;69:699-700
   PubMed Web of Science ®Google Scholar
• Sussman JD, Argov Z, McKee D, et al. Antisense treatment for myasthenia gravis: experience with Monarsen. Ann NY Acad Sci 2008;1132:283-90
   PubMed Web of Science ®Google Scholar
• Sussman J, Argov Z, Wirguin Y, et al. Further developments with antisense treatment for myasthenia gravis. Ann NY Acad Sci 2012;1275:13-16
   PubMed Web of Science ®Google Scholar
• Baggi F, Antozzi C, Toscani C, Cordiglieri C. Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades? Arch Immunol Ther Exp (Warsz) 2012;60:19-30
   PubMed Web of Science ®Google Scholar
• Souroujon MC, Brenner T, Fuchs S. Development of novel therapies for MG: studies in animal models. Autoimmunity 2010;43:446-60
   PubMed Web of Science ®Google Scholar
• Lazaridis K, Zisimopoulou P, Lagoumintzis G, et al. Antigen-specific apheresis of autoantibodies in myasthenia gravis. Ann NY Acad Sci 2012;1275:7-12
   Google Scholar
• Aricha R, Feferman T, Fuchs S, Souroujon MC. Ex vivo generated regulatory T cells modulate experimental autoimmune myasthenia gravis. J Immunol 2008;180:2132-9
   PubMed Web of Science ®Google Scholar
• Nessi V, Nava S, Rocco C, et al. Naturally occurring CD4+CD25+ regulatory T cells prevent but do not improve experimental myasthenia gravis. J Immunol 2010;185:5656-67
   PubMed Web of Science ®Google Scholar
• Sheng JR, Li LC, Ganesh BB, et al. Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia gravis. Clin Immunol 2008;128:172-80
   PubMed Web of Science ®Google Scholar
• Duan RS, Adikari SB, Huang YM, et al. Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells. Neurobiol Dis 2004;16:461-7
   PubMed Web of Science ®Google Scholar
• Xiao BG, Duan RS, Link H, Huang YM. Induction of peripheral tolerance to experimental autoimmune myasthenia gravis by acetylcholine receptor-pulsed dendritic cells. Cell Immunol 2003;223:63-9
   PubMed Web of Science ®Google Scholar
• Kong QF, Sun B, Wang GY, et al. BM stromal cells ameliorate experimental autoimmune myasthenia gravis by altering the balance of Th cells through the secretion of IDO. Eur J Immunol 2009;39:800-9
   PubMed Web of Science ®Google Scholar
• Yang H, Zhang Y, Wu M, et al. Suppression of ongoing experimental autoimmune myasthenia gravis by transfer of RelB-silenced bone marrow dentritic cells is associated with a change from a T helper Th17/Th1 to a Th2 and FoxP3+ regulatory T-cell profile. Inflamm Res 2010;59:197-205
   Google Scholar
• Lebrun C, Bourg V, Tieulie N, et al. Successful treatment of refractory generalized myasthenia gravis with rituximab. Eur J Neurol 2009;16:246-50
   Google Scholar
• Nelson Jr RP, Pascuzzi RM, Kessler K, et al. Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review. J Clin Neuromuscul Dis 2009;10:170-7
   Google Scholar
• Blum S, Gillis D, Brown H, et al. Use and monitoring of low dose rituximab in myasthenia gravis. J Neurol Neurosurg Psychiatry 2011;82:659-63
   PubMed Web of Science ®Google Scholar
• Diaz-Manera J, Martinez-Hernandez E, Querol L, et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 2012;78:189-93
   PubMed Web of Science ®Google Scholar
• Collongues N, Casez O, Lacour A, et al. Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study. Muscle Nerve 2012;46:687-91
   PubMed Web of Science ®Google Scholar
• Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177:362-71
   PubMed Web of Science ®Google Scholar
• Lisak RP, Ragheb S. The role of B cell-activating factor in autoimmune myasthenia gravis. Ann NY Acad Sci 2012;1274:60-7
   PubMed Web of Science ®Google Scholar
• Coles AJ, Twyman CL, Arnold DL, et al. CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380:1829-39
   PubMed Web of Science ®Google Scholar
• Cohen JA, Coles AJ, Arnold DL, et al. CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380:1819-28
   PubMed Web of Science ®Google Scholar
• Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010;61:35-47
   PubMed Web of Science ®Google Scholar
• Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012;366:1181-9
   PubMed Web of Science ®Google Scholar
• Christadoss P, Goluszko E. Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein. J Neuroimmunol 2002;122:186-90
   PubMed Web of Science ®Google Scholar
• Rowin J, Meriggioli MN, Tuzun E, et al. Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology 2004;63:2390-2
   PubMed Web of Science ®Google Scholar
• Tuzun E, Meriggioli MN, Rowin J, et al. Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment. J Autoimmun 2005;24:261-8
   PubMed Web of Science ®Google Scholar
• Fee DB, Kasarskis EJ. Myasthenia gravis associated with etanercept therapy. Muscle Nerve 2009;39:866-70
   PubMed Web of Science ®Google Scholar
• Aricha R, Mizrachi K, Fuchs S, Souroujon MC. Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis. J Autoimmun 2011;36:135-41
   PubMed Web of Science ®Google Scholar
• Christadoss P, Tuzun E, Li J, et al. Classical complement pathway in experimental autoimmune myasthenia gravis pathogenesis. Ann NY Acad Sci 2008;1132:210-19
   PubMed Web of Science ®Google Scholar
• Howard JF Jr, Barohn R, Freimer M, et al. Randomized, double-blind, placebo-controlled, crossover, multicenter, phase II study of eculizumab in patients with refractory generalized Myasthenia gravis. Abstract to 12th International Conference on Myasthenia Gravis and related disorders; 21 – 23 May 2012; New York. Neurology 2012;78(Meeting Abstracts 1):S35.004
   Google Scholar
• Soliven B, Rezania K, Gundogdu B, et al. Terbutaline in myasthenia gravis: a pilot study. J Neurol Sci 2009;277:150-4
   Google Scholar
• Gomez AM, Willcox N, Molenaar PC, et al. Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis? Ann NY Acad Sci 2012;1274:48-59
   PubMed Web of Science ®Google Scholar
• Hartung HP, Kieseier BC. Atacicept: targeting B cells in multiple sclerosis. Ther Adv Neurol Disord 2010;3:205-16
   PubMedGoogle Scholar
• Baggi F, Andreetta F, Caspani E, et al. Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis. J Clin Invest 1999;104:1287-95
   PubMed Web of Science ®Google Scholar
• Im SH, Barchan D, Fuchs S, Souroujon MC. Mechanism of nasal tolerance induced by a recombinant fragment of acetylcholine receptor for treatment of experimental myasthenia gravis. J Neuroimmunol 2000;111:161-8
   PubMed Web of Science ®Google Scholar
• Minisman G, Bhanushali M, Conwit R, et al. Implementing clinical trials on an international platform: challenges and perspectives. J Neurol Sci 2012;313:1-6
   Google Scholar
• Benatar M, Sanders DB, Burns TM, et al. Task Force on MG Study Design of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Recommendations for myasthenia gravis clinical trials. Muscle Nerve 2012;45:909-17
   PubMed Web of Science ®Google Scholar
• Murphy SM, Puwanant A, Griggs RC; Consortium for Clinical Investigations of Neurological Channelopathies (CINCH) and Inherited Neuropathies Consortium (INC) Consortia of the Rare Disease Clinical Research Network. Unintended effects of orphan product designation for rare neurological diseases. Ann Neurol 2012;72:481-90
   PubMed Web of Science ®Google Scholar